Physician profile

Jose Antonio Bouffard

Nuclear Imaging & Therapy · Detroit, MI

NPI 1043388788

$71,259.62

in general payments reported to CMS, 2019-2025

4 companies · $9,083 in 2025

The $9,083 reported for 2025 was more than what 94% of Nuclear Imaging & Therapy providers received nationally (typical 2025 total: $122).

See the full distribution for Nuclear Imaging & Therapy

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program$35,509.50
Travel and Lodging$5,380.48
Food and Beverage$2,290.03

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Ge Healthcare $70,331.09 2019-2025
Pinnacle, INC $775.00 2019
Si-Bone, INC. $124.53 2025
Heron Therapeutics, INC. $29.00 2022

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Jose Antonio Bouffard

$71,259.62

in general payments reported 2019-2025

Years
2019-2025
Top company
Ge Healthcare
Context
The $9,083 reported for 2025 was more than what 94% of Nuclear Imaging & Therapy providers received nationally (typical 2025 total: $122).

https://glasscript.com/doctor/138613/jose-antonio-bouffard

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.